Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Millennium Pharmacon International Tbk. (SDPC) vs Reksa Dana Indeks Premier ETF PEFINDO i-Grade (XIPI) Price & Performance

Millennium Pharmacon International Tbk.Trade
Reksa Dana Indeks Premier ETF PEFINDO i-GradeTrade

Price performance (Past 24H)

Key statistics

Millennium Pharmacon International Tbk. vs Reksa Dana Indeks Premier ETF PEFINDO i-Grade — how do they compare? Millennium Pharmacon International Tbk. trades at Rp182 (market cap 235.69B, 101.9K 24h volume), while Reksa Dana Indeks Premier ETF PEFINDO i-Grade trades at Rp178 (market cap 640.37B, 6.4K 24h volume). The key difference: Reksa Dana Indeks Premier ETF PEFINDO i-Grade is far larger — about 2.7× Millennium Pharmacon International Tbk.'s market cap, and Millennium Pharmacon International Tbk. is more actively traded (101.9K versus 6.4K). Which is the better fit depends on your goals.

SDPCXIPI
Market Cap
235.69B640.37B
Volume
101.9K6.4K
Lot
1.02K64
Turnover
18.68M1.14M
Average Price
183.35178.88
Value
18.68M1.14M

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

SDPC
View details

About Millennium Pharmacon International Tbk.

PT Millennium Pharmacon International Tbk (the Company) was established on October 20th, 1952 under the name N.V. Perusahaan Dagang SOEDARPO CORPORATION. On July 29th, 1997, the Extraordinary Shareholders meeting held by the Company has approved the sale of assets and of the whole share participation on the Company in PT Praweda Ciptakarsa Informatika and PT Sumber Daya Praweda Informatika. In order to strengthen its equity and settle the foreign currently loan, the Company has conducted its first Right Issue and has submitted the registration statement on May 8th, 2000 to the Capital Advisory Board (BAPEPAM). The Company started its operations on October 20, 1952. The name was changed from previous name PT NVPD Soedarpo Corporation.

Read more on SDPC

About Reksa Dana Indeks Premier ETF PEFINDO i-Grade

Read more on XIPI